TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks ...Middle East

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO, May 5,...

Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks )

Also on site :

• Giveaway: Enter to win tickets for ‘Hello, Dolly!’
• Hamas executes Palestinians for looting as desperation grows under Israeli blockade
• 3 injured in Denver shooting near Coors Field